Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Univariate analysis of HAI

From: Analysis of factors influencing hospital-acquired infection in postoperative patients with intracranial aneurysm

Relevant factorsInfection group
(n = 64)
Control group
(n = 478)
t/z/χ2P
Gender n (%)
 Male31 (48.4)194 (40.6)1.4330.231
 Female33 (51.6)284 (59.4)  
Age n (%)
  ≤ 44 years old8 (12.5)79 (16.5)2.7370.255
 45–59 years old28 (43.8)239 (50)  
  ≥ 60 years old28 (43.8)160 (33.5)  
Admission Activities of daily living (ADL) M(Q)30 (0–64)95 (45–100)−6.6990.000
Admission route n (%)
 Emergency47 (73.4)191 (40)25.6870.000
 Elective17 (26.6)287 (60)  
Hospitalization time M(Q)19 (15–24)8 (6–12)−10.2950.000
Mechanical ventilation n (%)
 Yes48 (75)76(15.9)111.7350.000
 No16 (25)402(84.1)  
Hypertension n (%)
 Yes23 (35.9)169 (35.4)0.0080.927
 No41 (64.1)309 (64.6)  
Diabetes n (%)
 Yes9 (14.1)69 (14.4)0.0060.936
 No55 (85.9)409 (85.6)  
Coronary heart disease n (%)
 Yes5 (7.8)19 (4)1.9640.161
 No59 (92.2)459 (96)  
Immune system disease n (%)
 Yes1 (1.6)7 (1.5)0.0040.952
 No63 (98.4)471 (98.5)  
Steroids n (%)
 Yes12 (18.8)115 (24.1)0.8870.346
 No52 (81.3)363 (75.9)  
Antiplatelet aggregate n (%)
 Yes11 (17.2)221 (46.2)19.4520.000
 No53 (82.8)257 (53.8)  
Admission GCS score n (%)
  ≤ 8 points25 (39.1)19 (4)93.1610.000
  > 8 points39 (60.9)459 (96)  
Admission Hunt-Hess classification n (%)
  ≤ 2 points35 (54.7)435 (91)64.6230.000
  ≥ 3 points29 (45.3)43 (9)  
Leukopenia n (%)
 Yes2 (3.1)19 (4)0.1090.741
 No62 (96.9)459 (96)  
Albumin reduction n (%)
 Yes14 (21.9)36 (7.5)13.8670.000
 No50 (78.1)442 (92.5)  
Hyperglycaemia n (%)
 Yes45 (70.3)166 (34.7)30.0620.000
 No19 (29.7)312 (65.3)  
Abnormal liver function n (%)
 Yes6 (9.4)43 (9)0.0100.921
 No58 (90.6)435 (91)  
Abnormal renal function n (%)
 Yes3 (4.7)5 (1)2.9470.086
 No61 (95.3)473 (99)  
Hyperkalaemia n (%)
 Yes1 (1.6)1 (0.2)0.3350.562
 No63 (98.4)477 (98.8)  
Hypokalaemia n (%)
 Yes9 (14.1)54 (11.3)0.4200.517
 No55 (85.9)424 (88.7)  
Hypernatremia n (%)
 Yes3 (4.7)14 (2.9)0.1420.707
 No61 (95.3)464 (97.1)  
Hyponatremia n (%)
 Yes12 (18.8)26 (5.4)13.3650.000
 No52 (81.3)452 (94.6)  
Surgical approach n (%)
 Intervention22 (34.4)320 (66.9)25.7160.000
 Craniotomy42 (65.6)158 (33.1)  
Surgery duration n (%)
  ≤ 4 h30 (46.9)365 (76.4)24.8250.000
  > 4 h34 (53.1)113 (23.6)  
Non-class I incision n (%)
 Yes1 (1.6)2 (0.4)0.9640.326
 No63 (98.4)476 (99.6)  
Surgical level n (%)
 Small01 (0.2)6.9140.075
 Medium1 (1.6)32 (6.7)  
 Large4 (6.3)9 (1.9)  
 Extra large59 (92.2)436 (91.2)  
Anaesthesia method n (%)
 General anaesthesia64 (100)465 (97.3)0.8110.368
 Local anaesthesia013 (2.7)  
Intraoperative blood loss n (%)
  < 1000 ml60 (93.8)473 (99)6.4450.011
  ≥ 1000 ml4 (6.3)5 (1)  
Unexpected reoperation n (%)
 Yes8 (12.5)8 (1.7)19.4680.000
 No56 (87.5)470 (98.3)  
Hypothermia treatment n (%)
 Yes26 (40.6)11 (2.3)124.3760.000
 No38 (59.4)467 (97.7)  
Artificial airway n (%)
 Yes64 (100)466 (97.5)0.6880.407
 No012 (2.5)  
Indwelling catheter n (%)
 Yes64 (100)474 (99.2)1.0090.315
 No04 (0.8)  
Central venous catheter n (%)
 Yes58 (90.6)119 (24.9)110.8830.000
 No6 (9.4)359 (75.1)